9 month results as of 30 september 2006 webcast 7 november peter wulff president & ceo 2 1 highlights r&d update 3 production 4 litigation 5 business development 6 financials news triggers agenda smallpox more than 200 subjects now vaccinated with imvamune data from studies in hiv patients advanced stage infection shows that the vaccine is safe and immunogenic two phase i ii trials mva bn polytope initiated kvistgård facility granted european manufacturing authorization ready for rfp iii order batch yield increased berlin released three vaccines clinical intellectual property rights a new patent on was issued to company by uspto itc initial determination concluded s patents are infringed but questions their validity product pipeline platform preclinical gmp pi pii piii nef multiantigen immunotherapy imvaboost cancer breast prostate other measles jev dengue rsv market programme vaccination 170 infected expected before year end double blinded randomised placebo controlled
